Richard S. Finn, MD, on Quality of Life With Tislelizumab Versus Sorafenib in HCC Treatment

Posted: Tuesday, January 31, 2023

Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses the clinical implications of study findings showing that patients with unresectable hepatocellular carcinoma (HCC) treated with first-line tislelizumab had better health-related quality-of-life outcomes compared with those treated with sorafenib, particularly in terms of fatigue and physical functioning. Its favorable safety profile and effects on overall survival and response rate suggest that tislelizumab may be a first-line treatment option for this patient population.